Relación entre el polimorfismo DRD2/ANKK1 y el desarrollo de complicaciones motoras en enfermedad de Parkinson

Introduction: Pharmacogenetic factors may influence the development of motor complications in subjects with Parkinson's disease. Specifically, the expression of polymorphisms of the gene for the dopamine receptor D2 (DRD2) have been implicated in a greater susceptibility for complications secondary to levodopa treatment. Objective: The objective of this study is to determine an association between DRD2 and Taq1A polymorphisms and the presence of motor complications due to levodopa treatment. Subjects and methods: We included 236 subjects with Parkinson's disease. The presence of motor complications was assessed by a movement disorders specialist. The genotypification of the Taq1A and DRD2-141C polymorphisms was done using restriction enzymes. Results: Sixty-nine percent of subjects were heterozygote (A1/A2) for the Taq1A polymorphism. In regards to the-141C polymorphism, 63.4% presented the Ins/Ins genotype. The-141C polymorphism Del/Del was significantly associated with motor fluctuations (P=0.04). Conclusions: The presence of -141C Del/Del appears to be associated with the development of motor fluctuations secondary to levodopa treatment in subjects with PD.